A study by Hong et al. showed that PARP inhibition promoted ferroptosis by repressing SLC7A11-mediated glutathione (GSH) biosynthesis in a p53-dependent manner and synergized with ferroptosis inducers in BRCA-proficient ovarian cancer [67]. This evidence concerns the gene TP53 and ovarian carcinoma.